An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
NCT ID: NCT05454488
Last Updated: 2025-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
30 participants
INTERVENTIONAL
2022-07-25
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
• To determine the effectiveness of an evidence-based focal cryotherapy ablation by measuring negative in-field recurrence rate at 6-months post-ablation.
Secondary Objectives:
* To determine quality of life following focal prostate cancer ablation using validated questionnaires (EPIC-26, AUA symptoms score, SHIM).
* To establish PSA kinetics post-evidence-based focal cryotherapy ablation.
* To determine rates of out of field recurrence on 6-month biopsy following focal cryotherapy ablation.
* To determine MRI findings post-focal cryotherapy ablation, including those related to prostate and surrounding periprostatic fat volume.
* To determine rate of progression and re-intervention collected as part of standard of care treatment for 5-year following study treatment.
* To describe financial toxicity associated with focal prostate cancer treatment using cryotherapy.
* To describe the incidence and severity of complications within 30-days after the study focal ablation treatment.
* To describe imaging findings on PSMA PET MRI performed in a subset of men after standard of care focal cryotherapy prior to 6-month biopsy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Focal therapy Treatment
Cryoablation is a procedure in which special needles are inserted into the tumor site.
Focal Cryoablation
Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area
Standard of Care
Participants will receive a prostate biopsy.
Quality-of-life Questionnaires
Participants will fill out questionnaires.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Focal Cryoablation
Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area
Standard of Care
Participants will receive a prostate biopsy.
Quality-of-life Questionnaires
Participants will fill out questionnaires.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Life expectancy over 10 years as assessed by treating physician
* Prior to enrollment, MRI fusion biopsy of MRI-visible lesion required (as detailed below, which includes systematic biopsy cores)
* Single focus GG2 or GG3 (additional GG1 allowed up to 6mm, noting that a single focus of disease is defined as an area seen on MRI that may be biopsied multiple times using targeted biopsies and have systematic core biopsies directly adjacent to targeted cores; all of which being considered as from the same focus)
* Histologically confirmed adenocarcinoma of prostate
* Organ-confined prostate cancer, clinical stage ≤T2bN0M0
* Visible tumor on MRI
* No clear evidence or high suspicion of extraprostatic extension or seminal vesical invasion on MRI
* Biopsy via transperineal or transrectal approach with at least 2 cores of MRI visible lesions that are PIRADS 2 or higher and 12 core systematic biopsy template (exclusion of cores from systematic template that overlap with targeted cores allowed).
* Additional performance of microultrasound guided biopsy is allowed though not required. Please note that every effort will be made to correlate microultrasound findings with MRI, in order to determine if positive results are from the same MRIvisible focus. This determination will be made by the surgeon performing the biopsy.
* Note that GGG 1 disease at sites other than ablation zone are allowed provided these are 6mm or less in size. PSA ≤15 ng/mL, or PSAD \<0.15 if PSA \>15 ng/mL
* Physician can fully visualize the prostate on transrectal ultrasound on entry biopsy
* Lesion anatomically amenable to cryotherapy treatment based on treating physician's discretion
* Willing and able to read, understand and sign the study specific informed consent document
* Willing and agreeable to comply with study protocol requirements, including focal cryotherapy ablation and all follow up visit requirements
* Patients must consent to investigative laboratory protocol (such as, but not limited to, 2021- 0560)
Exclusion Criteria
* Medical history or concurrent disease, which in the opinion of the investigator, poses the patient at significant peri-operative risk of complication due to anesthesia or the procedure
* Active urinary tract infection
* Any previous treatment for prostate cancer, including radiation therapy, hormonal treatment, biologic therapy for prostate cancer, or chemotherapy
* Prior TURP or other prostate outlet procedure such as HoLEP, greenlight, microwave ablation, aquablation, UroLift, or simple prostatectomy.
* Previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease
* Inability to obtain prostate MRI (ex. due to claustrophobia, pacemaker, or prohibitive implants)
* Unwilling to consent to laboratory investigative protocol (such as, but not limited to, 2021- 0560)
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Justin Gregg, MD
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
MD Anderson Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2022-05462
Identifier Type: OTHER
Identifier Source: secondary_id
2022-0165
Identifier Type: -
Identifier Source: org_study_id